SUO 2021: Targeting HIF-2alpha in Von-Hippel Lindau (VHL) Patients
Society of Urologic Oncology (SUO) 2021, targeting HIF-2alpha in von-Hippel Lindau (VHL) patients, VHL lesions, MK-6482 (Belzutifan) in patients with VHL, efficacy and safety of the belzutifan.
Source: urotoday.com